Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
12,683
datasets available to search
ShareScore release 0.9.0
Dataset results
12,683 results for “tolerability”
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
ClinicalTrials.gov study NCT03848845. IPD Sharing: YES. Countries: 4. Publications: 1.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD
ClinicalTrials.gov study NCT01039675. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults
ClinicalTrials.gov study NCT05891236. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
ClinicalTrials.gov study NCT00841763. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Stati
ClinicalTrials.gov study NCT03337308. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
ClinicalTrials.gov study NCT01059539. IPD Sharing: Not stated. Countries: 4. Publications: 1.
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
ClinicalTrials.gov study NCT01005901. IPD Sharing: Not stated. Countries: 11. Publications: 2.
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
ClinicalTrials.gov study NCT03201419. IPD Sharing: Not stated. Countries: 7. Publications: 1.
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
ClinicalTrials.gov study NCT00537511. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants
ClinicalTrials.gov study NCT05037409. IPD Sharing: NO. Countries: 1. Publications: 0.
PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril
ClinicalTrials.gov study NCT04656847. IPD Sharing: NO. Countries: 1. Publications: 1.
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
ClinicalTrials.gov study NCT02014558. IPD Sharing: YES. Countries: 3. Publications: 3.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
ClinicalTrials.gov study NCT02908685. IPD Sharing: Not stated. Countries: 16. Publications: 2.
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
ClinicalTrials.gov study NCT03524118. IPD Sharing: YES. Countries: 6. Publications: 2.
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
ClinicalTrials.gov study NCT01144624. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic
ClinicalTrials.gov study NCT04494256. IPD Sharing: YES. Countries: 4. Publications: 1.
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
ClinicalTrials.gov study NCT00724971. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants
ClinicalTrials.gov study NCT04366349. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
ClinicalTrials.gov study NCT02405091. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrroniu
ClinicalTrials.gov study NCT01727141. IPD Sharing: Not stated. Countries: 8. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.